REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—nivolumab, which helps the immune system attack cancer, and ASTX727, which targets abnormal cells—can shrink or stabilize B-cell lymphomas that have returned or stopped responding to standard treatments. About 32 adult…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New combo therapy offers hope for relapsed lymphoma patients
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. About 24 participants will receive the treatment …
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Radioactive antibody combo aims to beat back stubborn hodgkin lymphoma
Disease control Recruiting nowThis study tests a new approach for people with Hodgkin lymphoma that has returned or not responded to treatment. It combines a radioactive antibody (Y-90 anti-CD25) with standard chemotherapy (BEAM) before a stem cell transplant. The goal is to see if this combination improves h…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug HCB301 takes on tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants …
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated May 07, 2026 18:39 UTC